Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis - A randomized open-label controlled study

Liver International

Volumn 32, Issue 6, 2012, Pages 977-987

  Kim, Moon Young ^a   Cho, Mee Yon ^a   Baik, Soon Koo ^a   Jeong, Phil Ho ^a   Suk, Ki Tae ^b   Jang, Yoon Ok ^a   Yea, Chang Jin ^a   Kim, Jae Woo ^a   Kim, Hyun Soo ^a   Kwon, Sang Ok ^a   Yoo, Byung Su ^a   Kim, Jang Young ^a   Eom, Min Seob ^a   Cha, Seung Hwan ^a   Chang, Sei Jin ^a  

^a Yonsei University Wonju College of Medicine   (South Korea)

^b Hallym University College of Medicine   (South Korea)

Author keywords

Alcoholic liver disease; Angiotensin II; Hepatic fibrosis; Renin angiotensin system

Indexed keywords

CANDESARTAN; GELATINASE A; HYDROXYPROLINE; RAC1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; URSODEOXYCHOLIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BIOLOGICAL MARKERS; BIOPSY; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; SEVERITY OF ILLNESS INDEX; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84862813779     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02774.x     Document Type: Article

References (35)

1. Friedman SL, Roll FJ, Boyles J, et al. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci U S A 1985; 82: 8681-5.
2. Baik SK, Jo HS, Suk KT, et al. Inhibitory effect of angiotensin II receptor antagonist on the contraction and growth of hepatic stellate cells. Korean J Gastroenterol 2003; 42: 134-41.
3. Kim MY, Baik SK, Park DH, et al. Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model. J Gastroenterol 2008; 43: 889-96.
4. Park DH, Baik SK, Choi YH, et al. Inhibitory effect of angiotensin blockade on hepatic fibrosis in common bile duct-ligated rats. Korean J Hepatol 2007; 13: 61-9.
5. Sookoian S, Fernandez MA, Castano G. Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study. World J Gastroenterol 2005; 11: 7560-3.
6. Corey KE, Shah N, Misdraji J, et al. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int 2009; 29: 748-53.
7. Debernardi-Venon W, Martini S, Biasi F, et al. AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J Hepatol 2007; 46: 1026-33.
8. Terui Y, Saito T, Watanabe H, et al. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 2002; 36: 1022.
9. Ueki M, Koda M, Shimizu T, et al. Effect of an angiotensin-II type-1 receptor blocker, candesartan on hepatic fibrosis in chronic hepatitis C: a prospective study. Hepatogastroenterology 2009; 56: 1100-4.
10. Veldt BJ, Laine F, Guillygomarc'h A, et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol 2002; 36: 93-8.
11. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-31.
12. Gonzalez-Abraldes J, Albillos A, Banares R, et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001; 121: 382-8.
13. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999; 29: 334-9.
14. Trabut JB, Plat A, Thepot V, et al. Influence of liver biopsy on abstinence in alcohol-dependent patients. Alcohol Alcohol 2008; 43: 559-63.
15. Kim MY, Cho MY, Baik SK, et al. Histological subclassification of cirrhosis using Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol 2011; 55: 1004-9.
16. Kutami R, Girgrah N, Wanless IR, et al. The Laennec grading system for assessment of hepatic fibrosis: validation by correlation with wedged hepatic vein pressure and clinical features. Hepatology 2000; 32: 407A.
17. Wanless IR, Sweeney G, Dhillon AP, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002; 100: 1566-9.
18. Kleinder DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
19. Baik SK, Park DH, Kim MY, et al. Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity. J Gastroenterol 2003; 38: 1150-4.
20. Lee KI, Kong ID, Baik SK, et al. Characteristics of potassium and calcium currents of hepatic stellate cells (ito) in rat. Yonsei Med J 2004; 45: 649-60.
21. Pueyo ME, Arnal JF, Rami J, et al. Angiotensin II stimulates the production of NO and peroxynitrite in endothelial cells. Am J Physiol 1998; 274: C214-20.
22. Laursen JB, Rajagopalan S, Galis Z, et al. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997; 95: 588-93.
23. Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-8.
24. Fukui T, Ishizaka N, Rajagopalan S, et al. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 1997; 80: 45-51.
25. McClellan KJ, Goa KL. Candesartan cilexetil. A review of its use in essential hypertension. Drugs 1998; 56: 847-69.
26. Ojima M, Inada Y, Shibouta Y, et al. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol 1997; 319: 137-46.
27. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-45.
28. Otsuka M, Takahashi H, Shiratori M, et al. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax 2004; 59: 31-8.
29. Kim S, Iwao H. Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype. J Hypertens 1997;15: S3-7, Suppl.
30. Leuschner UF, Lindenthal B, Herrmann G, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52: 472-9.
31. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39: 770-8.
32. Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884-90.
33. Poupon RE, Lindor KD, Pares A, et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003; 39: 12-6.
34. Kim KA, Jeong SH. The diagnosis and treatment of primary biliary cirrhosis. Korean J Hepatol 2011; 17: 173-9.
35. Kim KA, Jeong SH, Lee JI, et al. Clinical features and prognosis of primary biliary cirrhosis in Korea. Korean J Hepatol 2011; 16: 139-46.